To keep drug prices high, pharma has been piling up the patents
Published . Updated .
Add-on patents have increased drug patent periods from two years to over six.
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Add-on patents have increased drug patent periods from two years to over six.
Source: Ars Technica
Acadia Healthcare (ACHC) since this story, compared with the market
Since the first closing price after “To keep drug prices high, pharma has been piling up the patents,” Acadia Healthcare (ACHC) is +7.70%. The S&P 500 fund (SPY) is +0.29% over the same days, a +7.41% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 28 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days after publication, inside 30 days. The filing is listed beside the story “To keep drug prices high, pharma has been piling up the patents.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 17 days before publication, inside 30 days. The filing is listed beside the story “To keep drug prices high, pharma has been piling up the patents.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “To keep drug prices high, pharma has been piling up the patents.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “To keep drug prices high, pharma has been piling up the patents.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “To keep drug prices high, pharma has been piling up the patents.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies carried with this story
- ACHC Acadia Healthcare
In “To keep drug prices high, pharma has been piling up the patents,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “To keep drug prices high, pharma has been piling up the patents,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “To keep drug prices high, pharma has been piling up the patents,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “To keep drug prices high, pharma has been piling up the patents,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “To keep drug prices high, pharma has been piling up the patents,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “To keep drug prices high, pharma has been piling up the patents,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
The 28 Sep 2026 story “To keep drug prices high, pharma has been piling up the patents” names Acadia Healthcare (ACHC) because of this story.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Ascendis Pharma A/S (ASND): GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“To keep drug prices high, pharma has been piling up the patents” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.